# 24-Week Recurrence Rate of Gout Following Firsekibart Treatment

> **NCT07625514** · NA · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, Zhejiang University, School of Medicine** · enrollment: 264 (estimated)

## Conditions studied

- Gout Flare

## Interventions

- **DRUG:** Firsekibart

## Key facts

- **NCT ID:** NCT07625514
- **Lead sponsor:** Second Affiliated Hospital, Zhejiang University, School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-07
- **Primary completion:** 2029-08-28
- **Final completion:** 2029-08-28
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625514, "24-Week Recurrence Rate of Gout Following Firsekibart Treatment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*